Travere Therapeutics, Inc. (TVTX) Q3 2025 10-Q Quarterly Report
Travere Therapeutics, Inc. (TVTX) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 30, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Travere Therapeutics, Inc. Q3 2025 10-Q Analysis
Risk Factors
- • New commercialization risk: FDA full approval of FILSPARI in Sept 2024 replacing prior accelerated approval in Feb 2023 requires expanded U.S. sales force training and market adoption efforts
- • Most material update: Expanded risks on third-party commercialization outside U.S. due to CSL Vifor acquisition by CSL Limited and possible reduced marketing support
Travere Therapeutics, Inc. Q3 2025 Quarterly FinancialsXBRL
Revenue
$165M
▲ +162.1% YoY▲ +44.0% QoQ
Net Income
$26M
▲ +146.9% YoY▲ +301.5% QoQ
Operating Margin
15.1%
▲ +10439bp YoY▲ +2618bp QoQ
Net Margin
15.6%
▲ +10274bp YoY▲ +2674bp QoQ
ROE
34.9%
Total Assets
$539M
EPS (Diluted)
$0.29
▲ +141.4% YoY▲ +307.1% QoQ
Operating Cash Flow
$14M
▲ +133.7% YoY▲ +187.3% QoQ
Source: XBRL data from Travere Therapeutics, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Travere Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.